JP Morgan Initiates Coverage On Rhythm Pharmaceuticals with Overweight Rating, Announces Price Target of $145
Rhythm Pharmaceuticals Inc RYTM
$99.25
▼ -6.14%
($-6.49)
⬇️ Below Yest. Low
📅 Earnings This Week
Open
$105.74
Prev Close
$105.74
Day Range
$98.44 – $106.87
52W Range
$74.50 – $122.20
Market Cap
$6.81B
Beta
1.98
EPS (TTM)
$-3.06
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2017-10-05 |
| Shares Out. | 68,530,000 |
| Website | rhythmtx.com/ ↗ |
| Phone | 18009279800 |
| Employees | 414 |
| Revenue | $60.1M |
| Gross Profit | $53.0M |
| Net Income | -$55.6M |
| Free Cash Flow | -$120.5M |
| Total Assets | $442.3M |
| Total Liabilities | $204.7M |
| Equity | $122.9M |
About Rhythm Pharmaceuticals Inc
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.
Rhythm Pharmaceuticals Inc is a publicly traded company under the ticker symbol RYTM on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
22 analysts (2026-07-01)